Connect with us

Technology

Aidoc Launches Seven New AI Solutions to Tackle Europe’s Healthcare Challenges

Published

4 months ago

on

Aidoc’s new CE-marked AI solutions make its offering one of the most comprehensive in the field, enabling rapid delivery of treatment to patients.

LONDON, Sept. 3, 2024 /PRNewswire/ — Today, Aidoc, a leading healthcare AI provider, introduced seven new AI solutions to the European healthcare market. These additions mark a significant expansion of Aidoc’s award-winning aiOS™ platform, which alerts radiologists and care teams to suspected urgent pathologies in medical images, ensuring rapid delivery of treatment to patients.

The new algorithms, which have now all achieved medical device CE-marking under MDR, include four solutions for notifying and triaging urgent pathologies: vessel occlusion, aortic dissection, vertebral compression fractures and malpositioned endotracheal tube. Alongside these, there are three new quantification solutions that provide standardised quantitative assessments of cardiovascular and neurological conditions: midline shift, coronary artery calcification and abdominal aortic measurement.

With this latest release, Aidoc’s aiOS™ platform now offers 26 AI solutions approved for the European market, including 17 homegrown algorithms and others developed through strategic partnerships. This comprehensive suite of CE-marked clinical AI solutions is deployed via the Aidoc aiOS™ platform, delivering a seamless and unified user experience. Together with Aidoc’s care coordination and patient follow-up features, this solidifies Aidoc as the leading provider of end-to-end AI solutions for healthcare.

“Health systems in Europe face severe challenges with increasing patient backlogs and staff shortages. To address these challenges, we are now taking clinical AI to the next level by increasing the speed and the scope of developing and implementing new AI-modules” said Alexander Boehmcker, VP Europe at Aidoc. “Aidoc has already established itself as the leading clinical AI platform. With the introduction of these new solutions, we have scaled up our capability to flag more pathologies, and provide important measurements with our new quantification solutions. Coupled with our platform’s ability to rapidly activate care teams and ensure robust patient follow-up, we’re poised to deliver better outcomes for patients and providers. I am especially proud that now all our Aidoc AI-modules are CE-marked under the new MDR”.

Aidoc’s AI platform, which is extensively deployed across Europe is already backed by substantial evidence demonstrating its effectiveness at tackling Europe’s healthcare challenges. Namely, a recent study using Aidoc’s AI at the Netherlands Cancer Institute reported a 98% reduction in patient wait times for notification of incidental pulmonary embolism, a common co-morbidity on Oncology patients (1).

Furthermore, providers themselves are experiencing the benefits of Aidoc’s AI, as evidenced by survey results presented by the leading Teleradiology provider Reif & Möller at the European Congress of Radiology in Vienna. These findings revealed that 97% of teleradiologists no longer wish to report without AI, with 85% reporting increased job satisfaction directly attributable to its implementation (2).

Aidoc’s introduction of these new AI solutions underscores its dedication to supporting Europe’s over-stretched healthcare systems. Already processing millions of patient scans each month, this latest release underscores Aidoc’s unwavering commitment to equipping providers with state-of-the-art tools to ensure better patient outcomes, driving positive change throughout the healthcare sector.

About Aidoc

Aidoc is a pioneer in clinical AI. We focus on aiding and empowering healthcare teams to optimise patient treatment, which results in improved economic value and clinical outcomes. Our clinically proven AI solutions eliminate silos, increase efficiencies, and improve outcomes by delivering critical information when and where care teams need it leading to immediate collective action. Built on Aidoc’s proprietary aiOS™, we analyse and aggregate medical data to enable care teams to operationalise the unexpected. Used in more than 1,000 medical centers worldwide, Aidoc is a market leader in CE and UKCA-marked solutions in clinical AI and its AI-based solutions cover 75 percent of patient populations, enabling physicians to make informed decisions based on real-time data. Aidoc AI is always on, running in the background to change the foreground.

References

1) Topff, L., Ranschaert, E.R., Bartels-Rutten, A., Negoita, A., Menezes, R., Beets-Tan, R.G. and Visser, J.J., 2023. Artificial intelligence tool for detection and worklist prioritization reduces time to diagnosis of incidental pulmonary embolism at CT. Radiology: Cardiothoracic Imaging, 5(2), p.e220163.

2) Poster no. C-13783: AI in Routine use across Germany and Austria – What are the experiences of Teleradiologists? Torsten Bert Thomas Moeller; Dillingen / Germany

Logo: https://mma.prnewswire.com/media/2015772/4883314/Aidoc_Always_On_AI_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aidoc-launches-seven-new-ai-solutions-to-tackle-europes-healthcare-challenges-302234917.html

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

The American Legion seeks entries for Fourth Estate Awards in media

Published

22 minutes ago

on

January 9, 2025

By

INDIANAPOLIS, Jan. 9, 2025 /PRNewswire/ — The American Legion has announced its call for entries in the annual Fourth Estate Awards competition for excellence in journalism and its positive impact on society. The deadline for submissions to be received or postmarked is March 15, 2025.

The American Legion presents the awards to recognize the outstanding achievements made in print and broadcast media. Website and podcast submissions are also encouraged to compete in the print or broadcast categories. In addition to the award, the winner in each category will be presented a $2,000 stipend to cover travel and lodging expenses to The American Legion National Convention in Tampa. The presentation will occur at approximately 9 am on August 28, 2025 at the Tampa Convention Center.

An entry form with contest rules can be found at https://www.legion.org/information-center/the-fourth-estate-award. You can also contact kchrisman@legion.org for further information.

Submissions are judged on the quality of the work and the impact that it had in producing a positive result for the community. The work must have been published, posted or broadcast in 2024.

All journalists or media outlets who believe their work improved society in a tangible and way are encouraged to submit their entry. There is no entry fee and no single medium is limited to the number of entries.

Past winners include CBS News, CNN, USA Today, WFTS (Tampa) and the Military Times. The complete list can be found at www.legion.org.

Media contacts: Katie Chrisman, (317) 630-1298, kchrisman@legion.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-legion-seeks-entries-for-fourth-estate-awards-in-media-302347119.html

SOURCE The American Legion

Continue Reading

Technology

CellFE® and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow

Published

22 minutes ago

on

January 9, 2025

By

ALAMEDA, Calif., Jan. 9, 2025 /PRNewswire/ — CellFE®, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced an innovative collaboration to create a hybrid workflow that seamlessly integrates non-viral and viral approaches to cell therapy engineering. This next-generation process aims to enable streamlined workflows of complex edited cells for biotech and pharmaceutical applications. 

CellFE® and Syenex announce collaboration on hybrid gene editing workflow ahead of the JP Morgan Healthcare Conference.

The collaboration application note will be officially unveiled the week of the highly anticipated J.P. Morgan Healthcare Conference in San Francisco this January, a premier event that brings together industry leaders, investors, and innovators from around the world.

“The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities into a streamlined workflow—one that preserves cell viability and functionality without compromise.” said Dr. Alla Zamarayeva, CEO of CellFE. “By collaborating with Syenex, we are directly addressing this critical need.”

Jay Rosanelli, CEO at Syenex, added: “This joint effort showcases the role of collaborative science in accelerating the creation of life-changing medicines for patients around the globe. We are thrilled to partner with CellFE and showcase the potential of this novel hybrid workflow to dramatically simplify manufacturing of genetic medicines.”

This collaboration comes at a pivotal time as allogeneic and autologous cell therapy providers seek more efficient manufacturing processes. A key challenge is developing gentler yet highly effective techniques for delivering gene-editing cargo to patient cells, as current methods—often involving viral transduction and electroporation—can be detrimental to cells and extend recovery and processing times, particularly for complex, sequential editing. This innovative hybrid workflow aims to overcome these challenges, enabling advanced genetic editing while preserving cell functionality and supporting streamlined workflows.

Both companies will be attending the J.P. Morgan Healthcare Conference this month from January 13-16th. Details on where to partner with the companies at the conference can be found below, along with contact information for both companies.

Partner with CellFE at the JP Morgan Healthcare Conference:

J.P. Morgan Healthcare Conference – Jan 13-16
Westin St. Francis in San Francisco, CABiotech Showcase – Jan 13-15
Hilton Union Square, San Francisco, CABio Partnering at JPMorgan Week – Jan 13-16
San Francisco Marriott Marquis in San Francisco, CA
cellfebiotech.com/meet

Partner with Syenex at the JP Morgan Healthcare Conference:

Bio Partnering at JPMorgan Week – Jan 13-16
San Francisco Marriott Marquis in San Francisco, CA
syenex.com/meet

About CellFE Biotech
CellFE, a cutting-edge microfluidics company, is transforming the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. CellFE aims to unlock the full potential of this transformative modality by tackling its key market challenges, notably high manufacturing costs and extended vein-to-vein timelines. With a focus on T-Cell, HSC, and iPSC-based therapies, CellFE’s microfluidics-based gene-delivery technology, in conjunction with proprietary best-in-class workflows, targets critical bottlenecks in cell therapy manufacturing. For more information, please visit www.cellfebiotech.com.

About Syenex
Syenex builds bioengineering technologies to unlock the future of human health. Leveraging the power of synthetic biology, we design scalable, precision-engineered gene delivery vectors, empowering cell and gene therapy developers to cure disease and build the next generation of medicines. Designed to break the barriers that slow medical progress, our Open Science model ensures global access to our expanding toolkit and a network of scale-up partners, accelerating the path of breakthroughs from idea to impact for all of academia and biopharma. Since 2022, Syenex has rapidly built a portfolio of cell-specific bioengineering systems and established partnerships across the fields of immune cell, stem cell, and hepatocyte engineering. Learn more and get started at www.syenex.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellfe-and-syenex-collaborate-to-advance-cell-engineering-with-hybrid-gene-editing-workflow-302347122.html

SOURCE CellFE

Continue Reading

Technology

The TreppWire Podcast Celebrates 300th Episode with Strategic Rebrand and Enhanced Vision

Published

22 minutes ago

on

January 9, 2025

By

Trepp announced today a rebrand and enhanced vision for The TreppWire Podcast ahead of its milestone 300th episode.

NEW YORK, Jan. 9, 2025 /PRNewswire-PRWeb/ — Trepp, a leading provider of data, insights, and technology solutions to the structured finance, commercial real estate (CRE), and banking markets announced today a rebrand and enhanced vision for The TreppWire Podcast ahead of its milestone 300th episode.  

“Powered by our marketing, research, and product groups, this show has been a trusted resource for the commercial real estate community, and we are excited to continue its growth,” said Hayley Keen, VP, Head of Marketing.

Since its launch in 2020, The TreppWire Podcast has garnered more than 1.7 million listens, establishing itself as a leading voice in the CRE industry, as well as the structured finance, banking, and broader economic markets. The podcast leverages Trepp’s proprietary commercial property, loan, and financial data and deep market expertise to provide weekly insights to industry professionals.

Complemented by a sleek new visual identity and modern design aesthetic, this strategic rebrand builds upon Trepp’s 40-year legacy of delivering timely, accurate, and comprehensive specialized CRE data and insights to help listeners make better, more informed decisions. Through market cycles, volatility, and periods of growth, The TreppWire Podcast remains committed to uncovering both challenges and opportunities, providing listeners with actionable insights to navigate market dynamics.

The rebrand also introduces an elevated format, which will include frequent industry expert guest appearances, as well as exclusive macroeconomic commentary from Trepp’s newly appointed Chief Economist, Rachel Szymanski. The podcast will continue to be a go-to resource for market participants, delivering timely insights from diverse industry perspectives.

“It is so exciting to watch our podcast hit the 300th episode milestone. Powered by our marketing, research, and product groups, this show has been a trusted resource for the commercial real estate community, and we are excited to continue its growth,” said Hayley Keen, VP, Head of Marketing. “The market has trusted Trepp’s data for more than 40 years, and with this rebrand, we’re not just maintaining that commitment – we’re elevating it. We’re enhancing the podcast experience while staying true to what our audience has always trusted us for: delivering reliable, actionable market intelligence that helps them make informed, confident decisions.”

Listeners can tune in to the newly rebranded The TreppWire Podcast on all major podcast platforms, including Apple Podcasts, Spotify, SoundCloud, and YouTube. Weekly episodes are released every Thursday. Check out our new website to learn more: https://www.trepp.com/the-treppwire-podcast

About Trepp 
Trepp, founded in 1979, is the leading provider of data, insights, and technology solutions to the structured finance, commercial real estate, and banking markets. Trepp provides primary and secondary market participants with the solutions and analytics they need to increase operational efficiencies, information transparency, and investment performance. From its offices in New York, Dallas, and London, Trepp serves its clients with products and services to support trading, research, risk management, surveillance, and portfolio management. Trepp subsidiary, Commercial Real Estate Direct, is a daily news source covering the commercial real estate capital markets. Trepp is owned by the Daily Mail and General Trust (DMGT)

Media Contact

Ennys Soydas, Trepp, Inc., 212-754-1010, press@trepp.com, www.trepp.com

Twitter

View original content to download multimedia:https://www.prweb.com/releases/the-treppwire-podcast-celebrates-300th-episode-with-strategic-rebrand-and-enhanced-vision-302346930.html

SOURCE Trepp, Inc.

Continue Reading

Trending